Situación actual de los pacientes VIH+ Esteban Martínez Hospital Clínic Barcelona

Size: px
Start display at page:

Download "Situación actual de los pacientes VIH+ Esteban Martínez Hospital Clínic Barcelona"

Transcription

1 Situación actual de los pacientes VIH+ Esteban Martínez Hospital Clínic Barcelona

2 Mortality per 1 patient-years HIV infection has changed from a fatal disease into a chronic condition This means long-term exposure to ART 3 8 ACTIVE PATIENTS Deaths New patients 5 Number of patients Data from Hospital Clinic, Barcelona

3 Patients with VL >5 copies/ml on ARV Better immunological and virological responses to ART 4143 subjects from 5 clinic cohorts in Europe and Canada 1 % with >5 copies/ml* Median CD4+ increase Median CD4+ increase *Data from 3111 patients on any ARV therapy at viral load measurement Lampe FC, et al. Conference on Retroviruses and Opportunistic Infections, 5

4 Probability of survival At least a 1-year shorter expected survival than age- and gender-matched controls 1 Survival from age 5 years (N=3,99).75 Population controls Late HAART ( 5) Early HAART ( ) Pre-HAART ( ) Age, years Lohse N, et al. Ann Intern Med 7; 146:

5 Adults with HIV diagnosed at increasing age Median, IQR CASCADE: age at seroconversion by year n= Year of SC Slide courtesy of Krishran Bharakan

6 Changing spectrum of causes of death in HIV-infected patients Mortality (n=964) France Mortality 5 1 st quarter (n=45) Proportion (%) Proportion (%) AIDS 47 AIDS 39 Cancer 11 Cancer 15 HCV 9 HCV 1 Cardiovascular 7 Cardiovascular 9 Bacterial infection 6 Suicide 6 Suicide 4 Non-AIDS related infection 4 Liver disease Accident Accident HBV Overdose Neurological disorder 1 Iatrogenic Overdose 1 HBV Metabolic 1 Bronchopulmonary disease Renal failure 1 1 Other infection Unknown 1 3 Liver disease Psychiatric illness Antiretroviral treatment 1 Other Unknown Lewden C, et al. Int J Epidemiol. 5;34: Lewden C et al. J Acquir Immune Defic Syndr 8; 48: 59-8

7 Traditional health related risk factors more prevalent among HIV-infected patients MACS/WIHS cohorts Some risk factors are higher in HIVinfected adults, many of which may be causally related to HIV and hence not a true confounder (lipids, DM) Closed circles, HIV+men; closed triangles, HIV+women. Open circles, HIV- men; open triangles, HIV- women Kaplan RC et al. Clin Infect Dis 7; 5:

8 Plasma concentration of hscrp (ng/ml) Markers of inflammation may persist at elevated levels despite ART 4, 35, 3, 5,, 15, 1, 5, N=115 HIV-infected patients N=3 HIV-uninfected matched controls * ** HIV uninfected HIV infected, untreated HIV infected, 3 months of ART HIV infected, 1 months of ART * P<.1 vs HIV uninfected ** P<.1 vs HIV infected, untreated Adapted from Kristoffersen US, et al. 15th CROI 8; Poster 953.

9 Percentage of activated CD4+ T cells Percentage of activated CD8+ T cells ART decreases immune activation, but levels remain high vs HIV-negative subjects CD4+ CD8+ 3 P<.1 3 P<.1 P<.1 P< HIV infected untreated (N=13) HIV infected treated (N=99) HIV uninfected (N=6) HIV infected untreated (N=13) HIV infected treated (N=99) HIV uninfected (N=6) Adapted from Hunt PW et al. J Infect Dis 3; 187:

10 ARTERIAL WALL ARTERIAL WALL HIV infects artery walls and Tat promotes endothelial dysfunction, and inflammation Monocyte MCP-1, VCAM-1, ICAM-1 Inflammation Endothelial dysfunction Tat Endothelin-1 CD4+ T Vasoconstriction Endothelial dysfunction 1. Eugenin EA et al. Am J Pathol 8; Liu K et al. Am J Physiol Lung Cell Mol Physiol 5; 3. Park IW et al. Blood 1; 4. Kanmogne GD et al. Biochem Biophys Res Commun 5

11 ARTERIAL WALL ARTERIAL WALL HIV promotes lipid accumulation in arterial walls leading to atherosclerosis Monocyte VIH Nef Nef Tat LDL LDL-ox HDL (PON-1) CD4+ T MCP-1, SDF-1, CXC3L1, RANTES. Foam cell HDL-inf VCAM, ICAM, proteoglycans. CD36

12 HIV favours plaque rupture and thrombus development leading to ischemic disease Induction of metaloproteases 1 Apoptosis of endothelial cells 1. Lopez-Herrera A et al. Biochim Biophys Acta 5;. Yano M et al. AIDS 7;

13 Endotheliumdependent FMD (%) Endotheliumdependent FMD (%) High sensitivity CRP (mg/l) ART decreases inflammation, but cannot restore endothelial integrity P =.3 HIV Negative Untr eated HAART HAART Untreated CRP HIV Negative Untreated HAART Hsue P, et al. CROI 1

14 HIV is an important independent risk factor for atherosclerosis Characteristic Estimated effect (mm) Internal carotid Common carotid HIV infection.15**.33* Male.13***.54*** Current smoker.17***.** Past smoker.9***.*** Diabetes.1***.6*** Age (per 1 years).16***.73*** Systolic BP (per 1 mmhg).5***.5*** Diastolic BP (per 1 mmhg) -.7*** -.6*** Total cholesterol (per 1 mg/dl).9***.4*** HDL (per 1 mg/dl) -.*** -.11*** *p<.1, **p<.1, ***p<.1; There was a significant gender interaction Grünfeld C et al. AIDS 9

15 Aging Drug consumption Tobacco Alcohol Cocaine Other? The risk of CV disease is increased in HIVinfected patients Metabolic abnormalities Dyslipidemia Insulin resistance / DM Patient Body fat changes Lipoatrophy Lipoaccumulation Degree of immunedeficiency CV disease Other? Antiretroviral drugs HIV (and other infections) PIs Dyslipidemia Insulin resistance? Body fat changes? Other? NRTIs Dyslipidemia? Insulin resistance? Body fat changes? Other? HIV, HCV, HBV?, other? Dyslipidemia Systemic inflammation Inmune activation Vascular infection

16 Poly-pathology is more common with increasing age and HIV Poly-pathology prevalence in cases and controls, stratified by age categories. The following co-morbidities were analysed: Hypertension, Type Diabetes, Cardiovascular Disease and Osteoporosis. Poly-pathology prevalence was higher in cases than controls in all age strata (all p-values <.1). Poly-pathology prevalence in cases aged 41-5 was similar to that in controls aged >6 (p=.8). Guaraldi G et al. Poster 77 - CROI 1

17 HIV infection leads to premature ageing Normal ageing (average age in many clinics now around 5) Lifestyle risk factors (smoking, drug and alcohol misuse) Drug toxicity (for example tenofovir and renal disease) Persistent immune dysfunction and inflammation Premature ageing Adapted from Deeks SG, Phillips AN. Br Med J 9; 338:a317

18

19 Emerging co-morbidities in HIV+: HIV+ ~1-15 years older than HIV- Renal dysfunction 3% of HIV+ patients have abnormal kidney function 1 Reduced bone mineral density Increased prevalence of osteoporosis or osteopenia in spine, hip or forearm: 63% of HIV+ patients 1. Gupta SK et al. Clin Infect Dis 5;4: Brown TT et al. J Clin Endocrinol Metab 4;89(3): Clifford DB. Top HIV Med 8;16(): Triant VA et al. J Clin Endocrinol Metab 7;9: Patel P et al. Ann Intern Med 8;148: Cancer Increased risk of non- AIDS-defining cancers e.g. anal, vaginal, liver, lung, melanoma, leukemia, colorectal and renal 5 Neurocognitive dysfunction Neurological impairment present in 5% HIV+ patients 3 Cardiovascular disease 75% increase in risk of acute MI 4 Frailty Increased frailty phenotype if HIV infected 3-14x; Associated with CD4 count

20 Events Per 1 PYs Events Per 1 PYs HIV-infected patients have a higher incidence of myocardial infarction A 1 n = 3,851 RR 1.75 p <.1* B n = 1,44, HIV+ HIV- # of MI 189 6, Age Group (Years) * Adjusted for age, gender, race, hypertension, diabetes and dyslipidaemia. Proportion of patients with hypertension, diabetes and dyslipidaemia significantly higher in HIV-positive vs HIV-negative cohort Triant V et al., JCEM, 7

21 Reduced Bone Mineral Density in HIV+ Patients risk with age, duration HIV infection and CD4 count Brown TT & Qaqish RB. AIDS. 6; : Overton T et al. CROI 7. Abstract 836

22 Fracture prevalence/1 persons Greater rate of fractures in HIV-infected versus uninfected individuals HIVp<.1 Population-based study 8,55 HIV-infected patients,8,79 non HIV-infected patients HIV P<.1 p=.1 p<.1 All Vertebral Hip Wrist Adapted from Triant VA et al. J Clin Endocrinol Metab 8;93:

23 Liver and kidney comorbidities more common in HIV+ patients Liver Disease Renal Disease* Goulet J. Clin Infect Dis 7; 45:

24 Non-AIDS defining cancer rates higher in HIV+ patients vs general population Cancer Type, Observed Rate per 1, Person-Years (95% CI) ASD/HOPS (157,819 Person-Years) SEER (334,8,11 Person-Years) SRR* (95% CI) Anal 51.4 ( ) 1.5 ( ) 4.9 ( ) Vaginal 33.9 ( ) 3. (3.-3.3) 1. ( ) Hodgkin s lymphoma 51.4 ( ) 3.3 ( ) 14.7 ( ) Liver 31.7 ( ) 5.3 (5.-5.4) 7.7 ( ) Lung 88.8 ( ) 67.5 ( ) 3.3 (.8-3.9) Melanoma 4.7 ( ) 18.4 ( ).6 ( ) Oropharyngeal 33. ( ) 16.1 ( ).6 ( ) Leukemia 15. (9.8-.7) 1. ( ).5 ( ) Colorectal 47. ( ) 5. ( ).3 (1.8-.9) Renal 14. ( ) 13. ( ) 1.8 (1.1-.7) Prostate 3.7 ( ) ( ).6 (.4-8) ASD, Adult and Adolescent Spectrum of Disease Project; HOPS, HIV Outpatient Study; SEER, Surveillance, Epidemiology, and End Results, 199 3; *SRR, standardized rate ratio calculated as ASD/HOPS to SEER populations. Patel P et al. Ann Intern Med 8; 148:

25

26 Summary The HIV infected population is ageing HIV may affect the natural ageing process Co-morbidities are increasingly apparent ART needs to be chosen not only for providing long-term efficacy but also for having the lowest impact on ageing comorbidities

Prevalence of Comorbidities among HIV-positive patients in Taiwan

Prevalence of Comorbidities among HIV-positive patients in Taiwan Prevalence of Comorbidities among HIV-positive patients in Taiwan Chien-Ching Hung, MD, PhD Department of Internal Medicine National Taiwan University Hospital, Taipei, Taiwan % of participants Comorbidity

More information

Report Back from CROI 2010

Report Back from CROI 2010 Report Back from CROI 2010 Conference on Retroviruses and Opportunistic Infections Edwin Charlebois, MPH PhD Associate Professor of Medicine Department of Medicine University of California, San Francisco

More information

HIV Infection as a Chronic Disease. Howard Libman, MD Beth Israel Deaconess Medical Center Harvard Medical School

HIV Infection as a Chronic Disease. Howard Libman, MD Beth Israel Deaconess Medical Center Harvard Medical School HIV Infection as a Chronic Disease Howard Libman, MD Beth Israel Deaconess Medical Center Harvard Medical School Role of Primary Care Approximately 50,000 patients are diagnosed with HIV infection annually

More information

BHIVA Workshop: When to Start. Dr Chloe Orkin Dr Laura Waters

BHIVA Workshop: When to Start. Dr Chloe Orkin Dr Laura Waters BHIVA Workshop: When to Start Dr Chloe Orkin Dr Laura Waters Aims To use cases to: Review new BHIVA guidance Explore current data around when to start To discuss: Medical decisions, pros and cons Luigi

More information

HIV & Aging: Evolving Clinical Considerations in the New Millennium

HIV & Aging: Evolving Clinical Considerations in the New Millennium HIV & Aging: Evolving Clinical Considerations in the New Millennium Julian Falutz, MD, FRCP (C) Director, HIV Metabolic Clinic Immunodeficiency Treatment Centre Senior Physician Division of Geriatrics

More information

Optimizing Health While Aging with HIV

Optimizing Health While Aging with HIV Slide 1 Optimizing Health While Aging with HIV Todd T. Brown, MD, PhD Division of Endocrinology and Metabolism Johns Hopkins University Unfortunately, We are Not Slide 2 Immortal But How Do We Want to

More information

Primary Care for Persons Living with HIV

Primary Care for Persons Living with HIV Primary Care for Persons Living with HIV Brian Montague, DO MS MPH Assistant Professor of Medicine Division of Infectious Diseases Warren Alpert School of Medicine Brown University Outline What constitutes

More information

Pitavastatin 4 mg vs. Pravastatin 40 mg in HIV Dyslipidemia: Post- Hoc Analysis of the INTREPID Trial Based on the Independent CHD Risk Factor for Age

Pitavastatin 4 mg vs. Pravastatin 40 mg in HIV Dyslipidemia: Post- Hoc Analysis of the INTREPID Trial Based on the Independent CHD Risk Factor for Age Pitavastatin 4 mg vs. Pravastatin 40 mg in HIV Dyslipidemia: Post- Hoc Analysis of the INTREPID Trial Based on the Independent CHD Risk Factor for Age Craig A. Sponseller, Masaya Tanahashi, Hideki Suganami,

More information

The purpose. What are some of the comorbidities MORE IMPORTANTLY ARE THEY REALLY RELATED TO HIV AT ALL

The purpose. What are some of the comorbidities MORE IMPORTANTLY ARE THEY REALLY RELATED TO HIV AT ALL The purpose What are some of the comorbidities MORE IMPORTANTLY ARE THEY REALLY RELATED TO HIV AT ALL The answer Comorbidities exist need to be handled BUT relationship with HIV enormous implications for

More information

Primary Care of the HIV-infected Adult: If I Can Do It, You Can Do It

Primary Care of the HIV-infected Adult: If I Can Do It, You Can Do It Primary Care of the HIV-infected Adult: If I Can Do It, You Can Do It Howard Libman, MD Professor of Medicine, Emeritus Harvard Medical School Boston, Massachusetts Learning Objectives After attending

More information

Hans Strijdom SA Heart Meeting November 2017

Hans Strijdom SA Heart Meeting November 2017 Hans Strijdom SA Heart Meeting November 2017 HIV-infection and ART, but not high sensitivity CRP, are associated with markers of vascular function: Results from the Western Cape cohort of the EndoAfrica

More information

HIV Infection in the Long-term Survivor (Older Patient)

HIV Infection in the Long-term Survivor (Older Patient) HIV Infection in the Long-term Survivor (Older Patient) Howard Libman, MD Professor of Medicine, Harvard Medical School Beth Israel Deaconess Medical Center Boston, Massachusetts Learning Objectives Define

More information

HIV and Bone Disease: Through Thick and Thin! Pablo Tebas, MD

HIV and Bone Disease: Through Thick and Thin! Pablo Tebas, MD HIV and Bone Disease: Through Thick and Thin! Pablo Tebas, MD April 30 th, 2016 Disclosures I serve in an adjudication panel in a VZV vaccine study (Glaxo) I consult for Merck My research is supported

More information

No Conflict of Interest

No Conflict of Interest No Conflict of Interest Aging and HIV Co-Morbidities: A Challenge for Engagement in Care Maria L Alcaide M.D. Division of Infectious Diseases University of Miami Miller School of Medicine Objectives Understand

More information

HIV 101: Overview of the Physiologic Impact of HIV and Its Diagnosis Part 2: Immunologic Impact of HIV and its Effects on the Body

HIV 101: Overview of the Physiologic Impact of HIV and Its Diagnosis Part 2: Immunologic Impact of HIV and its Effects on the Body HIV 101: Overview of the Physiologic Impact of HIV and Its Diagnosis Part 2: Immunologic Impact of HIV and its Effects on the Body Melissa Badowski, PharmD, BCPS, AAHIVP Clinical Assistant Professor University

More information

Introduction to HIV and Aging

Introduction to HIV and Aging Introduction to HIV and Aging Sheree Starrett MD Medical Director - Rivington House June 27, 2008 Rivington House Objectives Know the demographics of aging and HIV Identify the similarities between aging

More information

HIV: A Chronic Condition

HIV: A Chronic Condition JOURNAL OF INSURANCE MEDICINE Copyright E 2015 Journal of Insurance Medicine J Insur Med 2015;45:136 141 INSURABILITY FOR HIV INFECTED INDIVIDUALS HIV: A Chronic Condition Daniel D. Zimmerman, MD By virtue

More information

Patient concerns. Will I grow old prematurely? Will I dement? Will I get heart disease?

Patient concerns. Will I grow old prematurely? Will I dement? Will I get heart disease? An Italian patient Patient concerns Will I grow old prematurely? Will I dement? Will I get heart disease? Causes of death among Danish HIV patients compared to population controls in the period 1995-2008

More information

Statin Use and Cardiovascular Disease in HIV

Statin Use and Cardiovascular Disease in HIV Statin Use and Cardiovascular Disease in HIV Steven K. Grinspoon, MD Professor of Medicine Harvard Medical School Boston, Massachusetts FLOWED: 04/18/16 Los Angeles, California: April 25, 2016 Statin Use

More information

Dr Paddy Mallon. Mater Misericordiae University Hospital, Dublin, Ireland. BHIVA AUTUMN CONFERENCE 2014 Including CHIVA Parallel Sessions

Dr Paddy Mallon. Mater Misericordiae University Hospital, Dublin, Ireland. BHIVA AUTUMN CONFERENCE 2014 Including CHIVA Parallel Sessions BHIVA AUTUMN CONFERENCE 2014 Including CHIVA Parallel Sessions Dr Paddy Mallon Mater Misericordiae University Hospital, Dublin, Ireland 9-10 October 2014, Queen Elizabeth II Conference Centre, London BHIVA

More information

Human immunodeficiency virus

Human immunodeficiency virus Panarteritis: beyond the vulnerable plaque Human immunodeficiency virus Stockholm, August 30, 2010 Giuseppe Schillaci Department of Clinical and Experimental Medicine University of Perugia Perugia, Italy

More information

COMPETING INTEREST OF FINANCIAL VALUE

COMPETING INTEREST OF FINANCIAL VALUE BHIVA AUTUMN CONFERENCE 2012 Including CHIVA Parallel Sessions Dr Duncan Churchill Royal Sussex County Hospital, Brighton COMPETING INTEREST OF FINANCIAL VALUE > 1,000: Speaker Name Statement Duncan Churchill

More information

PIs are the real world answer for the chronic patient s management. Giovanni Guaraldi

PIs are the real world answer for the chronic patient s management. Giovanni Guaraldi PIs are the real world answer for the chronic patient s management Giovanni Guaraldi HIV MEDICATION TOXICITY Ageing with HIV: The clinical consequences AGEING Heart disease Kidney disease Liver disease

More information

Mortalité et Morbidité à l ère des traitements antirétroviraux dans les Pays du Nord

Mortalité et Morbidité à l ère des traitements antirétroviraux dans les Pays du Nord Mortalité et Morbidité à l ère des traitements antirétroviraux dans les Pays du Nord Laurence WEISS Hôpital Européen Georges Pompidou, Université Paris-Descartes Paris, France Deaths per 100 Person-Years

More information

HIV and Cardiovascular Disease: Epidemiology, Mechanisms, and Clinical Implications

HIV and Cardiovascular Disease: Epidemiology, Mechanisms, and Clinical Implications HIV and Cardiovascular Disease: Epidemiology, Mechanisms, and Clinical Implications Matthew J. Feinstein, MD, MSc Assistant Professor of Medicine Northwestern University Feinberg School of Medicine Chicago,

More information

Ischemic Heart and Cerebrovascular Disease. Harold E. Lebovitz, MD, FACE Kathmandu November 2010

Ischemic Heart and Cerebrovascular Disease. Harold E. Lebovitz, MD, FACE Kathmandu November 2010 Ischemic Heart and Cerebrovascular Disease Harold E. Lebovitz, MD, FACE Kathmandu November 2010 Relationships Between Diabetes and Ischemic Heart Disease Risk of Cardiovascular Disease in Different Categories

More information

Supplemental Table S2: Subgroup analysis for IL-6 with BMI in 3 groups

Supplemental Table S2: Subgroup analysis for IL-6 with BMI in 3 groups Supplemental Table S1: Unadjusted and Adjusted Hazard Ratios for Diabetes Associated with Baseline Factors Considered in Model 3 SMART Participants Only Unadjusted Adjusted* Baseline p-value p-value Covariate

More information

New Insights in Pathogenesis Inflammation and Immune Activation

New Insights in Pathogenesis Inflammation and Immune Activation Activity Code TM809 New Insights in Pathogenesis Inflammation and Immune Activation Turner Overton, M.D. Associate Professor of Medicine University of Alabama at Birmingham Learning Objectives Upon completion

More information

Trends in Malignancies Among HIV-Infected Patients. Roger Bedimo, MD, MS VA North Texas Health Care System UT Southwestern Medical Center

Trends in Malignancies Among HIV-Infected Patients. Roger Bedimo, MD, MS VA North Texas Health Care System UT Southwestern Medical Center Trends in Malignancies Among HIV-Infected Patients Roger Bedimo, MD, MS VA North Texas Health Care System UT Southwestern Medical Center Denver, April 2011 Learning Objectives At the conclusion of this

More information

Novedades en la prevención y control de las comorbilidades asociadas al VIH

Novedades en la prevención y control de las comorbilidades asociadas al VIH IX Congreso Nacional GeSIDA Vigo, 28 Noviembre-1 Diciembre 2017 Novedades en la prevención y control de las comorbilidades asociadas al VIH Esteban Martinez estebanm@clinic.ub.es Comorbidities in HIV+

More information

HIV e infarto miocardico: un problema dimenticato?

HIV e infarto miocardico: un problema dimenticato? HIV e infarto miocardico: un problema dimenticato? Leonardo Calza Clinica di Malattie Infettive, Policlinico S.Orsola-Malpighi, Università degli Studi di Bologna CVD and HIV disease. The current issues

More information

ROLE OF INFLAMMATION IN HYPERTENSION. Dr Barasa FA Physician Cardiologist Eldoret

ROLE OF INFLAMMATION IN HYPERTENSION. Dr Barasa FA Physician Cardiologist Eldoret ROLE OF INFLAMMATION IN HYPERTENSION Dr Barasa FA Physician Cardiologist Eldoret Outline Inflammation in CVDs the evidence Basic Science in Cardiovascular inflammation: The Main players Inflammation as

More information

HIV/HCV co-infected patients should be prioritised for HCV treatment. Sanjay Bhagani Royal Free Hospital/UCL London

HIV/HCV co-infected patients should be prioritised for HCV treatment. Sanjay Bhagani Royal Free Hospital/UCL London HIV/HCV co-infected patients should be prioritised for HCV treatment Sanjay Bhagani Royal Free Hospital/UCL London Also requires other resources What should a prioritisation process Life-saving at this

More information

Ageing with HIV. Amsterdam Institute for Global Health and Development. University of Amsterdam The Netherlands

Ageing with HIV. Amsterdam Institute for Global Health and Development. University of Amsterdam The Netherlands Ageing with HIV Peter Reiss Professor of Medicine Dept of Infectious Diseases, Tropical Medicine and Aids and Dept of Global Health Academic Medical Center Amsterdam Institute for Global Health and Development

More information

ASSOCIATION BETWEEN CARDIOVASCULAR DISEASE & CONTEMPORARILY USED PROTEASE INHIBITORS

ASSOCIATION BETWEEN CARDIOVASCULAR DISEASE & CONTEMPORARILY USED PROTEASE INHIBITORS ASSOCIATION BETWEEN CARDIOVASCULAR DISEASE & CONTEMPORARILY USED PROTEASE INHIBITORS L Ryom, JD Lundgren, W El-Sadr, P Reiss, A Phillips, O Kirk, R Weber, E Fontas, AD Monforte, S de Wit, F Dabis, CI Hatleberg,

More information

Primary Care of the HIV-infected Adult: If I Can Do It, You Can Do It

Primary Care of the HIV-infected Adult: If I Can Do It, You Can Do It Primary Care of the HIV-infected Adult: If I Can Do It, You Can Do It Howard Libman, MD Professor of Medicine, Emeritus Harvard Medical School Boston, Massachusetts Learning Objectives After attending

More information

Diabetes Mellitus: A Cardiovascular Disease

Diabetes Mellitus: A Cardiovascular Disease Diabetes Mellitus: A Cardiovascular Disease Nestoras Mathioudakis, M.D. Assistant Professor of Medicine Division of Endocrinology, Diabetes, & Metabolism September 30, 2013 1 The ABCs of cardiovascular

More information

Endothelial dysfunction and subclinical atherosclerosis in HIV/HCV- coinfected patients in the Lower Silesia Region, Poland

Endothelial dysfunction and subclinical atherosclerosis in HIV/HCV- coinfected patients in the Lower Silesia Region, Poland Endothelial dysfunction and subclinical atherosclerosis in HIV/HCV- coinfected patients in the Lower Silesia Region, Poland Katarzyna Barska 1,2, Wiesława Kwiatkowska 1,2, Brygida Knysz 1,3, Justyna Drelichowska

More information

Cardiovascular Complications of HIV and Its Treatment

Cardiovascular Complications of HIV and Its Treatment Cardiovascular Complications of HIV and Its Treatment FORMATTED: 11/6/15 Marshall J. Glesby, MD, PhD Professor of Medicine, Healthcare Policy and Research Weill Cornell College of Medicine New York, New

More information

John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam

John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam Latest Insights from the JUPITER Study John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam Inflammation, hscrp, and Vascular Prevention

More information

(n=6279). Continuous variables are reported as mean with 95% confidence interval and T1 T2 T3. Number of subjects

(n=6279). Continuous variables are reported as mean with 95% confidence interval and T1 T2 T3. Number of subjects Table 1. Distribution of baseline characteristics across tertiles of OPG adjusted for age and sex (n=6279). Continuous variables are reported as mean with 95% confidence interval and categorical values

More information

Metabolic consequences of HIV-induced inflammation

Metabolic consequences of HIV-induced inflammation Metabolic consequences of HIV-induced inflammation Jacqueline Capeau INSERM U938, Université Pierre et Marie Curie Faculté de Médecine, site Saint-Antoine, Hôpital Tenon, Paris, France 1. Pathogenesis

More information

D:A:D Study Teaching Material

D:A:D Study Teaching Material D:A:D Study Teaching Material Data Collection of Adverse events of anti-hiv Drugs (D:A:D) study December 2012 - CHIP Background The D:A:D Study, is a prospective cohort study (collaboration) initiated

More information

50+ SHADES OF GREY, AGING WITH HIV

50+ SHADES OF GREY, AGING WITH HIV 50+ SHADES OF GREY, AGING WITH HIV R E B E C C A G L A S S M A N, M D I N S T R U C T O R O F M E D I C I N E, H A R V A R D M E D I C A L S C H O O L MR. C 71 years old Diagnosed with HIV in 1998 at the

More information

Outline. Epidemiology of Pediatric HIV 10/3/2012. I have no financial relationships with any commercial entity to disclose

Outline. Epidemiology of Pediatric HIV 10/3/2012. I have no financial relationships with any commercial entity to disclose Nutritional, Metabolic, and Gastrointestinal Complications in Pediatric HIV Infection Tracie L. Miller, MD Department of Pediatrics University of Miami, Miller School of Medicine I have no financial relationships

More information

D:A:D: Cumulative Exposure to DRV/r Increase MI Risk

D:A:D: Cumulative Exposure to DRV/r Increase MI Risk D:A:D: Cumulative Exposure to DRV/r Increase MI Risk 20.0-15.0-10.0-5.0-4.0-3.0-2.0-1.0- Unadjusted CVD rate ratios per 5 years additional exposure: ATV/r 1.25 [1.10-1.43] and DRV/r 1.93 [1.63-2.28] Adjusted*

More information

Aging and Cancer in HIV

Aging and Cancer in HIV Aging and Cancer in HIV Ronald Mitsuyasu, MD Professor of Medicine Director, UCLA Center for Clinical AIDS Research and Education Group Chairman, AIDS Malignancy Consortium (AMC) Age distribution of HIV-infected

More information

PART VI! IMPLICATIONS FOR THERAPIES

PART VI! IMPLICATIONS FOR THERAPIES PART VI! IMPLICATIONS FOR THERAPIES Background Current HIV and aging treatment advice: Start ART early and manage traditional risk factors for non-aids-related diseases aggressively Treatments to reverse

More information

All biomarkers at higher level in HIV group

All biomarkers at higher level in HIV group Supplemental Table S1: Summary of studies assessing mainly inflammatory biomarkers and their association with mortality and clinical endpoints in HIV infection First author, year, country Biomarkers measured

More information

BHIVA Best of CROI Feedback Meetings. London Birmingham North West England Cardiff Gateshead Edinburgh

BHIVA Best of CROI Feedback Meetings. London Birmingham North West England Cardiff Gateshead Edinburgh BHIVA Best of CROI Feedback Meetings London Birmingham North West England Cardiff Gateshead Edinburgh BHIVA Best of CROI Feedback Meetings 2010 COMPLICATIONS OF HIV DISEASE AND TREATMENT Overview Cardiovascular

More information

Mortality in HIV Infection: Monitoring Quality Outcomes

Mortality in HIV Infection: Monitoring Quality Outcomes Mortality in HIV Infection: Monitoring Quality Outcomes March 15, 2017 Steven Johnson MD Director, University of Colorado HIV/AIDS Clinical Program; Professor of Medicine, Division of Infectious Diseases;

More information

Five chapters 1. What is CVD prevention 2. Why is CVD prevention needed 3. Who needs CVD prevention 4. How is CVD prevention applied 5. Where should CVD prevention be offered Shorter, more adapted to clinical

More information

C E L I A J. M A X W E L L, M. D

C E L I A J. M A X W E L L, M. D H I V / A I D S I N O L D E R I N D I V I D U A L S T H E G R A Y I N G O F T H E D I S E A S E E X T E N U A T I N G V S M I T I G A T I N G F A C T O R S C E L I A J. M A X W E L L, M. D., F A C P A

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

HIV Update For the Internist

HIV Update For the Internist HIV Update For the Internist Disclosures I declare that I have received no incentives, financial or otherwise, from pharmaceutical or biomedical companies relevant to the content of this talk. As an Infectious

More information

ΛΟΙΜΩΞΗ HIV. Ιγνάτιος Οικονομίδης,MD,FESC Β Πανεπιστημιακή Καρδιολογική

ΛΟΙΜΩΞΗ HIV. Ιγνάτιος Οικονομίδης,MD,FESC Β Πανεπιστημιακή Καρδιολογική ΛΟΙΜΩΞΗ HIV Ιγνάτιος Οικονομίδης,MD,FESC Β Πανεπιστημιακή Καρδιολογική Κλινική, Νοσοκομείο «Αττικόν» Infection Acute Myocardial Infarction p er 100,000 HIV/AIDS discharg es 800 700 600 500 400 300 200

More information

Heart Disease in the HIV + Person

Heart Disease in the HIV + Person NORTHWEST AIDS EDUCATION AND TRAINING CENTER Heart Disease in the HIV + Person Ted Gibbons, MD January 15, 2015 Section Chief, Cardiology Harborview Medical Center University of Washington School of Medicine

More information

HIV and Co-morbidities November 18, 2013, 3:10 pm Abstract Number 141

HIV and Co-morbidities November 18, 2013, 3:10 pm Abstract Number 141 Low omega-3 index in erythrocytes is a risk factor for progression of atherosclerosis in people living with HIV Bianca M Arendt, M Smieja, IE Salit, DWL Ma, F Smaill, D Elston, E Lonn, Johane P Allard

More information

Frailty and age are independently associated with patterns of HIV antiretroviral use in a clinical setting. Giovanni Guaraldi

Frailty and age are independently associated with patterns of HIV antiretroviral use in a clinical setting. Giovanni Guaraldi Frailty and age are independently associated with patterns of HIV antiretroviral use in a clinical setting Giovanni Guaraldi Potential conflicts of interest Research funding: Jansen, Gilead, MSD, BMS Consultancies:

More information

PART IV! CLINICAL IMPLICATIONS

PART IV! CLINICAL IMPLICATIONS PART IV! CLINICAL IMPLICATIONS Background Biological link between HIV and aging paints a grim picture, however The benefits of ART strongly outweigh the risks associated with ongoing immune activation

More information

ISCHEMIC VASCULAR DISEASE (IVD) MEASURES GROUP OVERVIEW

ISCHEMIC VASCULAR DISEASE (IVD) MEASURES GROUP OVERVIEW ISCHEMIC VASCULAR DISEASE (IVD) MEASURES GROUP OVERVIEW 2014 PQRS OPTIONS F MEASURES GROUPS: 2014 PQRS MEASURES IN ISCHEMIC VASCULAR DISEASE (IVD) MEASURES GROUP: #204. Ischemic Vascular Disease (IVD):

More information

HIGH BURDEN OF METABOLIC COMORBIDITIES IN A CITYWIDE COHORT OF HIV OUTPATIENTS

HIGH BURDEN OF METABOLIC COMORBIDITIES IN A CITYWIDE COHORT OF HIV OUTPATIENTS HIGH BURDEN OF METABOLIC COMORBIDITIES IN A CITYWIDE COHORT OF HIV OUTPATIENTS Evolving Health Care Needs of People Aging with HIV in Washington, DC Matthew E. Levy 1, Alan E. Greenberg 1, Rachel Hart

More information

Top 10 Things to Know About the Older Patient With HIV Infection

Top 10 Things to Know About the Older Patient With HIV Infection Top 10 Things to Know About the Older Patient With HIV Infection Howard Libman, MD Professor of Medicine, Emeritus Harvard Medical School Beth Israel Deaconess Medical Center Boston, Massachusetts Learning

More information

Chronic complications of HIV infection. An update Pablo Tebas, MD

Chronic complications of HIV infection. An update Pablo Tebas, MD Activity Code TM809 Chronic complications of HIV infection. An update 2014 Pablo Tebas, MD Learning Objectives Upon completion of this presentation, learners should be better able to: Identify and update

More information

CLINICAL OUTCOME Vs SURROGATE MARKER

CLINICAL OUTCOME Vs SURROGATE MARKER CLINICAL OUTCOME Vs SURROGATE MARKER Statin Real Experience Dr. Mostafa Sherif Senior Medical Manager Pfizer Egypt & Sudan Objective Difference between Clinical outcome and surrogate marker Proper Clinical

More information

Inflammation and and Heart Heart Disease in Women Inflammation and Heart Disease

Inflammation and and Heart Heart Disease in Women Inflammation and Heart Disease Inflammation and Heart Disease in Women Inflammation and Heart Disease What is the link between een inflammation and atherosclerotic disease? What is the role of biomarkers in predicting cardiovascular

More information

HIV AND CEREBROVASCULAR DISEASE: AN INTERSECTION OF EPIDEMICS

HIV AND CEREBROVASCULAR DISEASE: AN INTERSECTION OF EPIDEMICS HIV AND CEREBROVASCULAR DISEASE: AN INTERSECTION OF EPIDEMICS Felicia C. Chow, MD, MAS University of California, San Francisco Departments of Neurology and Medicine (Infectious Diseases) September 26,

More information

CONSIDERATIONS FOR THE HIV POSITIVE WOMAN DURING MENOPAUSE

CONSIDERATIONS FOR THE HIV POSITIVE WOMAN DURING MENOPAUSE CONSIDERATIONS FOR THE HIV POSITIVE WOMAN DURING MENOPAUSE Dr. Sharon Walmsley University Health Network, Toronto, Ontario Canadian HIV Clinical Trials Network Objectives To review the epidemiology of

More information

Case discussion: How do drugs/patients impact need and type of monitoring CASE 2

Case discussion: How do drugs/patients impact need and type of monitoring CASE 2 Case discussion: How do drugs/patients impact need and type of monitoring CASE 2 Marta Boffito Head of Clinical Trials, St. Stephen s Centre (SSAT) Consultant Physician, Chelsea and Westminster Foundation

More information

The impact of antiretroviral drugs on Cardiovascular Health

The impact of antiretroviral drugs on Cardiovascular Health The impact of antiretroviral drugs on Cardiovascular Health José López-Sendón Hospital Universitario La Paz. IdiPaz Madrid. Spain Research grants and honoraria from (research committees, clinical trials,

More information

Correlation of novel cardiac marker

Correlation of novel cardiac marker Correlation of novel cardiac marker and mortality in EGAT population. Soluble ST2 hscrp Poh Chanyavanich, MD SukitYamwong, MD Piyamitr Sritara, MD Ramathibodi hospital Background hscrp - the most widely

More information

JUPITER NEJM Poll. Panel Discussion: Literature that Should Have an Impact on our Practice: The JUPITER Study

JUPITER NEJM Poll. Panel Discussion: Literature that Should Have an Impact on our Practice: The JUPITER Study Panel Discussion: Literature that Should Have an Impact on our Practice: The Study Kaiser COAST 11 th Annual Conference Maui, August 2009 Robert Blumberg, MD, FACC Ralph Brindis, MD, MPH, FACC Primary

More information

Coagulation and Morbidity in Treated HIV Infection. Michael M. Lederman, MD Scott R. Inkley Professor of Medicine Case Western Reserve University

Coagulation and Morbidity in Treated HIV Infection. Michael M. Lederman, MD Scott R. Inkley Professor of Medicine Case Western Reserve University Coagulation and Morbidity in Treated HIV Infection Michael M. Lederman, MD Scott R. Inkley Professor of Medicine Case Western Reserve University Although survival has improved, predicted life expectancy

More information

The JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009

The JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009 The JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009 Learning Objectives 1. Understand the role of statin therapy in the primary and secondary prevention of stroke 2. Explain

More information

Spotty Calcification as a Marker of Accelerated Progression of Coronary Atherosclerosis : Insights from Serial Intravascular Ultrasound

Spotty Calcification as a Marker of Accelerated Progression of Coronary Atherosclerosis : Insights from Serial Intravascular Ultrasound Spotty Calcification as a Marker of Accelerated Progression of Coronary Atherosclerosis : Insights from Serial Intravascular Ultrasound Department of Cardiovascular Medicine Heart and Vascular Institute

More information

Comorbidities: a moving area. Paul De Munter ARC Leuven BREACH

Comorbidities: a moving area. Paul De Munter ARC Leuven BREACH Comorbidities: a moving area Paul De Munter ARC Leuven BREACH 27-11-2015 Contents Introduction Comorbidities Cardiovascular disease and lipids Diabetes mellitus Hepatitis C Frailty Conclusion Introduction

More information

Guidelines on cardiovascular risk assessment and management

Guidelines on cardiovascular risk assessment and management European Heart Journal Supplements (2005) 7 (Supplement L), L5 L10 doi:10.1093/eurheartj/sui079 Guidelines on cardiovascular risk assessment and management David A. Wood 1,2 * 1 Cardiovascular Medicine

More information

Abacavir is associated with increased risk of cardiovascular disease in HIV-infected patients: A UK clinic case-control study

Abacavir is associated with increased risk of cardiovascular disease in HIV-infected patients: A UK clinic case-control study Abacavir is associated with increased risk of cardiovascular disease in HIV-infected patients: A UK clinic case-control study Collins Iwuji, Duncan Churchill, Yvonne Gilleece, Martin Fisher Brighton and

More information

Disclosures. Outline. Outline. Lipids, Statins and HIV: Topics in Clinical Management

Disclosures. Outline. Outline. Lipids, Statins and HIV: Topics in Clinical Management Disclosures Lipids, Statins and HIV: Topics in Clinical Management Medical Management of AIDS & Hepatitis December 10, 2016 Research grant support from Gilead Sciences for work in East Africa related to

More information

Dyslipidaemia. Is there any new information? Dr. A.R.M. Saifuddin Ekram

Dyslipidaemia. Is there any new information? Dr. A.R.M. Saifuddin Ekram Dyslipidaemia Is there any new information? Dr. A.R.M. Saifuddin Ekram PhD,FACP,FCPS(Medicine) Professor(c.c.) & Head Department of Medicine Rajshahi Medical College Rajshahi-6000 New features of ATP III

More information

Forget me not: providing care for people living with HIV and dementia (What does the future hold for our elderly HIV patients?)

Forget me not: providing care for people living with HIV and dementia (What does the future hold for our elderly HIV patients?) Forget me not: providing care for people living with HIV and dementia (What does the future hold for our elderly HIV patients?) Dr Simon Rackstraw FRCP Medical Director, Mildmay Hospital, London Consultant

More information

Supplementary Material*

Supplementary Material* Supplementary Material* Park LS, Tate JP, Sigel K, Brown ST, Crothers K, Gibert C, et al. Association of Viral Suppression With Lower AIDS-Defining and Non AIDS-Defining Cancer Incidence in HIV-Infected

More information

Factors Associated with Limitations in Daily Activity Among Older HIV+ Adults

Factors Associated with Limitations in Daily Activity Among Older HIV+ Adults Factors Associated with Limitations in Daily Activity Among Older HIV+ Adults KM Erlandson, K Wu, R Kalayjian, S Koletar, B Taiwo, FJ Palella Jr, K Tassiopoulos and the A5322 Team Background Growing burden

More information

AGING KIDNEY IN HIV DISEASE

AGING KIDNEY IN HIV DISEASE AGING KIDNEY IN HIV DISEASE Michael G. Shlipak, MD, MPH Professor of Medicine, Epidemiology and Biostatistics, UCSF Chief, General Internal Medicine, San Francisco VA Medical Center Kidney, Aging and HIV

More information

HIV-1 Dual Infection and Neurocognitive Impairment

HIV-1 Dual Infection and Neurocognitive Impairment HIV-1 Dual Infection and Neurocognitive Impairment Gabriel Wagner, MD Assistant Professor of Medicine Infectious Diseases & Global Public Health UC San Diego HIV-Associated End Organ Damage Antiretroviral

More information

Cascade of medical care to HIV-infected patients in Europe. Cristina Mussini

Cascade of medical care to HIV-infected patients in Europe. Cristina Mussini Cascade of medical care to HIV-infected patients in Europe Cristina Mussini UNAIDS: New HIV treatment target 90% of people tested 90% of people diagnosed with HIV on treatment 90% of people on treatment

More information

Immunologic Failure and Chronic Inflammation. Steven G. Deeks Professor of Medicine University of California, San Francisco

Immunologic Failure and Chronic Inflammation. Steven G. Deeks Professor of Medicine University of California, San Francisco Immunologic Failure and Chronic Inflammation Steven G. Deeks Professor of Medicine University of California, San Francisco Plasma HIV RNA (log) 6 5 4 3 2 52 year old HIV+/HCV+ man presents with symptomatic

More information

Disclosure Information

Disclosure Information Cardiovascular Risk and HIV Infection Albany Medical College June 3, 2010 Marshall Glesby Disclosure Information Research Support: Pfizer (Wyeth pneumococcal vaccine clinical trial) 1 Overview Coronary

More information

Dyslipidemia and HIV NORTHWEST AIDS EDUCATION AND TRAINING CENTER

Dyslipidemia and HIV NORTHWEST AIDS EDUCATION AND TRAINING CENTER NORTHWEST AIDS EDUCATION AND TRAINING CENTER Dyslipidemia and HIV Heidi Crane, MD, MPH Madison Metabolic Clinic Associate Professor UW Department of Medicine Presentation prepared by: Heidi Crane, MD,

More information

STABILITY Stabilization of Atherosclerotic plaque By Initiation of darapladib TherapY. Harvey D White on behalf of The STABILITY Investigators

STABILITY Stabilization of Atherosclerotic plaque By Initiation of darapladib TherapY. Harvey D White on behalf of The STABILITY Investigators STABILITY Stabilization of Atherosclerotic plaque By Initiation of darapladib TherapY Harvey D White on behalf of The STABILITY Investigators Lipoprotein- associated Phospholipase A 2 (Lp-PLA 2 ) activity:

More information

Sally L. Hodder M.D. Professor of Medicine New Jersey Medical School UMDNJ Newark, New Jersey

Sally L. Hodder M.D. Professor of Medicine New Jersey Medical School UMDNJ Newark, New Jersey Sally L. Hodder M.D. Professor of Medicine New Jersey Medical School UMDNJ Newark, New Jersey At the conclusion of this presentation, participants should be able to: Select appropriate antiretroviral therapy

More information

Dyslipidemia in the light of Current Guidelines - Do we change our Practice?

Dyslipidemia in the light of Current Guidelines - Do we change our Practice? Dyslipidemia in the light of Current Guidelines - Do we change our Practice? Dato Dr. David Chew Soon Ping Senior Consultant Cardiologist Institut Jantung Negara Atherosclerotic Cardiovascular Disease

More information

Novel Markers of Arterial Dysfunction

Novel Markers of Arterial Dysfunction 혈관연구회창립심포지움, 3 월 3 일, 2005 Novel Markers of Arterial Dysfunction Kwang Kon Koh, MD, FACC, FAHA Cardiology Gachon Medical School Incheon, Korea Atherosclerosis: A progressive process PHASE I: Initiation

More information

Diastolic dysfunction predicts impaired aerobic capacity in older HIVinfected

Diastolic dysfunction predicts impaired aerobic capacity in older HIVinfected Diastolic dysfunction predicts impaired aerobic capacity in older HIVinfected men Hillary McClintic Virginia Tech Carilion School of Medicine John Gottdiener, MD Kristina Crothers, MD Adeel A. Butt, MD

More information

Care of The Older Adult with HIV Infection

Care of The Older Adult with HIV Infection Care of The Older Adult with HIV Infection Howard Libman, MD Professor of Medicine, Harvard Medical School Director, HIV Program, Healthcare Associates Beth Israel Deaconess Medical Center Boston, Massachusetts

More information

Apelin and Visfatin Plasma Levels in Healthy Individuals With High Normal Blood Pressure

Apelin and Visfatin Plasma Levels in Healthy Individuals With High Normal Blood Pressure Apelin and Visfatin Plasma Levels in Healthy Individuals With High Normal Blood Pressure CI Liakos, 1 EA Sanidas, 1 DN Perrea, 1 V Gennimata, 1 V Chantziara, 1 CA Grassos, 2 N-A Viniou, 1 JD Barbetseas,

More information

Tesamorelin Clinical Data Overview Jean-Claude Mamputu, PhD Senior Medical Advisor, Theratechnologies

Tesamorelin Clinical Data Overview Jean-Claude Mamputu, PhD Senior Medical Advisor, Theratechnologies Tesamorelin Clinical Data Overview Jean-Claude Mamputu, PhD Senior Medical Advisor, Theratechnologies Copyright 2016. All Rights Reserved. Property of Theratechnologies Inc. Mechanism of Action of Tesamorelin

More information

Non alcoholic fatty liver disease and atherosclerosis Raul Santos, MD

Non alcoholic fatty liver disease and atherosclerosis Raul Santos, MD Non alcoholic fatty liver disease and atherosclerosis Raul Santos, MD Sao Paulo Medical School Hospital Sao Paulo, Brazil Disclosure Honoraria received for consult and/or speaker : Astra Zeneca, Amgen,

More information

Tra falsi miti e realtà Danno osseo e HIV: ciò che veramente conosciamo. Cristina Gervasoni ASST FBF Sacco

Tra falsi miti e realtà Danno osseo e HIV: ciò che veramente conosciamo. Cristina Gervasoni ASST FBF Sacco Tra falsi miti e realtà Danno osseo e HIV: ciò che veramente conosciamo Cristina Gervasoni ASST FBF Sacco Outline What do I know? What do we know? What have we learned lately? Outline What do we know?

More information

Dispelling the myths: HIV, ageing and the changing causes of morbidity Caroline A Sabin

Dispelling the myths: HIV, ageing and the changing causes of morbidity Caroline A Sabin Dispelling the myths: HIV, ageing and the changing causes of morbidity Caroline A Sabin Centre for Clinical Research, Epidemiology, Modelling and Evaluation (CREME), UCL, London, UK Disclosures I have

More information